Nyrada Quarterly Activities Report & Appendix 4C

Highlights:
•Cholesterol-Lowering Program:
-New PCSK9 inhibitor candidate identified and progressing to assessment.
-Alternative applications for NYX-1492 investigated.
-Peer-reviewed journal paper noting anti-inflammatory properties of NYX-1492 to be published.

•Brain Injury Program:
-Presentation on pathophysiological role of TRPC ion channels delivered at US Department of Defense Military Health System Research Symposium.
-Formulation work and planning for NYX-BI03 Good Laboratory Practice (GLP) study.
-Peer-reviewed journal paper published validating the pathophysiological role of TRPC ion channels in preventing brain injury progression.

•Sound position:
-R&D tax rebate of $3.2 million expected (subject to Government agency review).
-Pursuing non-dilutive funding opportunities in Australia and US.
-Cash position of $2.3 million as at 30 September 2023.